wnt8a Antibody

What is WNT8A and why is it important in research?

WNT8A, also known as WNT8D, belongs to the Wnt family of secreted signaling proteins that act as ligands for members of the frizzled family of seven transmembrane receptors. This protein has been implicated in critical developmental processes, particularly the regulation of cell fate and patterning during embryogenesis . WNT8A plays an especially important role in the development and differentiation of certain forebrain structures .

Research into WNT8A has revealed its significant involvement in body axis extension in vertebrates. While WNT8A is required for this process in lower vertebrates, in mammals WNT3A appears to take on the primary role, with WNT8A contributing to normal development of the anterior trunk when WNT3A is absent . This functional redundancy highlights the evolutionary conservation and developmental importance of Wnt signaling pathways.

WNT8A also cooperates with WNT3A to maintain FGF8 expression and prevent premature SOX2 upregulation in the axial stem cell niche, which is critical for posterior growth during embryogenesis . These findings underscore the importance of WNT8A in understanding fundamental developmental processes and potentially in addressing developmental disorders.

What are the validated applications for WNT8A antibodies?

WNT8A antibodies have been validated for multiple experimental applications in research settings. According to available data, WNT8A antibody 30518-1-AP has been specifically validated for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)/Immunocytochemistry (ICC), and ELISA applications .

For Western Blot applications, the antibody has been successfully used with Caco-2 cells, HT-29 cells, SW480 cells, and rat heart tissue . This spectrum of validated cell lines and tissues suggests broad utility across different experimental systems, particularly those investigating colorectal biology and cardiac tissue.

In Immunohistochemistry applications, WNT8A antibody has been validated for human colon cancer tissue detection, with specific antigen retrieval protocols recommended for optimal results . For Immunofluorescence/Immunocytochemistry applications, successful detection has been demonstrated in HCT 116 cells, a human colorectal carcinoma cell line .

Each application requires specific optimization of antibody dilution ratios. For Western Blot, a dilution range of 1:500-1:1000 is recommended; for Immunohistochemistry, 1:50-1:500; and for Immunofluorescence/ICC, 1:200-1:800 . These parameters provide starting points for experimental design, though researchers should validate optimal conditions for their specific experimental systems.

What tissue-specific considerations should researchers account for when using WNT8A antibodies?

When working with WNT8A antibodies, researchers should consider tissue-specific expression patterns and potential cross-reactivity issues. Based on validated applications, WNT8A antibody has demonstrated particular utility in colorectal cancer research contexts, with positive detection in colon cancer tissue and colorectal cell lines including Caco-2, HT-29, SW480, and HCT 116 cells . This suggests a strong foundation for WNT8A investigation in gastrointestinal research applications.

Antigen retrieval methods significantly impact immunohistochemical detection of WNT8A. For colon cancer tissue, TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 may serve as an alternative . This pH-dependent retrieval efficiency underscores the importance of optimizing tissue preparation protocols for each specific tissue type.

Researchers should also consider that the observed molecular weight of WNT8A protein ranges from 39-45 kDa, compared to its calculated weight of 39 kDa . This variation may reflect post-translational modifications or tissue-specific processing that could affect antibody recognition in different tissue contexts.

How can researchers optimize Western Blot protocols for WNT8A detection?

Sample preparation represents a critical consideration for WNT8A detection. Given that WNT8A has an observed molecular weight range of 39-45 kDa , researchers should select gel systems and running conditions that provide optimal resolution in this molecular weight range. Standard SDS-PAGE with 10-12% polyacrylamide gels typically offers sufficient resolution for WNT8A separation and subsequent transfer.

For protein transfer, semi-dry or wet transfer systems can be employed, with transfer conditions optimized for proteins in the 39-45 kDa range. Given that WNT8A is a secreted protein, researchers should consider analyzing both cellular lysates and conditioned media to capture the full spectrum of WNT8A expression and processing.

Blocking conditions significantly impact background signal and specificity. While standard blocking buffers containing 5% non-fat dry milk or BSA in TBST are typically effective, systematic optimization of blocking conditions may enhance signal-to-noise ratios. Extended blocking times (1-2 hours at room temperature or overnight at 4°C) may provide superior results for WNT8A detection.

For validation and troubleshooting purposes, researchers should consider including positive control samples from validated cell lines such as Caco-2, HT-29, SW480, or rat heart tissue . When investigating novel tissue sources or experimental conditions, these controls provide critical reference points for assessing antibody performance and specificity.

What are the key considerations for immunohistochemical detection of WNT8A?

Immunohistochemical detection of WNT8A requires careful optimization of fixation, antigen retrieval, and antibody incubation parameters. The recommended antibody dilution range for WNT8A antibody 30518-1-AP in IHC applications is 1:50-1:500 , though optimal dilution should be determined empirically for each tissue type and experimental condition.

Antigen retrieval represents a particularly critical step for successful WNT8A detection. For human colon cancer tissue, TE buffer at pH 9.0 is specifically recommended, with citrate buffer at pH 6.0 serving as an alternative option . The pH dependency of WNT8A epitope exposure underscores the importance of systematically evaluating different antigen retrieval conditions. Researchers should consider performing parallel staining with both recommended buffers to determine optimal conditions for their specific tissue samples.

Fixation protocols significantly impact epitope preservation and antibody accessibility. While standard 10% neutral buffered formalin fixation is compatible with WNT8A detection, optimization of fixation duration may enhance staining quality. For frozen sections, brief post-fixation in 4% paraformaldehyde followed by careful permeabilization often provides superior results compared to standard protocols.

Background reduction strategies are particularly important for WNT8A IHC. Endogenous peroxidase quenching should be thoroughly performed, and careful optimization of blocking solutions is advised. For tissues with high background potential, inclusion of species-matched normal serum in blocking solutions and extended blocking durations may significantly enhance signal specificity.

For validation of staining specificity, researchers should consider including known positive control tissues such as human colon cancer samples . Additionally, comparative analysis with alternative WNT8A antibodies or correlation with mRNA expression data provides valuable confirmation of staining patterns and specificity.

How do WNT8A antibodies perform in knockout/mutation validation studies?

WNT8A antibodies should be rigorously validated using genetic knockout systems to confirm specificity and performance characteristics. Research utilizing WNT8A knockout mice provides valuable resources for such validation studies. The WNT8A knockout mouse line described in the literature carries a deletion encompassing all exons of WNT8A , making it an ideal negative control system for antibody validation.

When evaluating antibody specificity using knockout systems, researchers should process wild-type and knockout tissues or cells in parallel, maintaining identical experimental conditions throughout sample preparation, antibody incubation, and detection steps. Complete absence of signal in knockout samples, contrasted with specific detection in wild-type samples, provides robust confirmation of antibody specificity.

For mutation studies, researchers can utilize the genotyping strategy described in the literature, which employs mutant primers (5′-GGT AGG AGA CCT GCT TCA GC-3′ and 5′-GTC TGT CCT AGC TTC CTC ACT G-3′) that generate an 81 bp PCR product, and wild-type primers (5′-GCT TCC GTC ATC TTC TTA GCA C-3′ and 5′-GGG CAC TCC TAA CCC TGT C-3′) that generate a 361 bp PCR product . This genotyping approach ensures precise identification of mutant status for correlation with antibody detection patterns.

The availability of double knockout systems for WNT8A and WNT3A provides additional validation opportunities and research platforms. These double knockout embryos exhibit distinctive phenotypes, including ectopic SOX2-positive neural-like tissue in the paraxial mesoderm compartment and increased SOX2 expression in the caudal epiblast . Correlation of antibody detection patterns with these well-characterized phenotypes offers powerful validation of antibody specificity and performance.

For advanced functional studies, comparison of WNT8A antibody staining patterns with in situ hybridization results provides valuable correlation between protein and mRNA expression. The availability of well-characterized in situ hybridization probes for WNT8A facilitates such comparative analyses.

How do WNT8A and WNT3A functionally cooperate in developmental processes?

WNT8A and WNT3A exhibit significant functional cooperation in vertebrate developmental processes, particularly in the regulation of body axis extension and axial stem cell niche maintenance. Research utilizing WNT8A−/− and WNT3A−/− single and double mutant mouse embryos has revealed important insights into their cooperative functions .

While WNT3A is primarily required for body axis extension in mammals, WNT8A contributes to normal development of the anterior trunk in the absence of WNT3A . This functional redundancy suggests evolutionary conservation of Wnt signaling mechanisms across vertebrate lineages, with WNT8A playing a more prominent role in lower vertebrates and WNT3A assuming the primary role in mammals.

The molecular basis for this cooperation centers on their joint regulation of key developmental genes. WNT8A and WNT3A together maintain appropriate FGF8 expression and prevent premature SOX2 upregulation in the axial stem cell niche, which is critical for posterior growth . Analysis of double knockout embryos demonstrates that loss of both WNT8A and WNT3A results in ectopic SOX2-positive neural-like tissue in the paraxial mesoderm compartment, even at early developmental stages (E8.25, 5-somite stage) .

Furthermore, double knockout embryos exhibit a pronounced increase in SOX2 expression in the caudal epiblast, reaching levels typically observed only in the neural plate of wild-type embryos . This observation indicates that WNT8A and WNT3A cooperatively maintain the caudal epiblast in an undifferentiated "SOX2-low" state, which appears critical for proper axis extension and tissue patterning.

The temporal expression pattern of WNT8A provides further insight into its cooperative function with WNT3A. WNT8A is expressed only during early somite stages and contributes specifically to anterior trunk development , suggesting a stage-specific cooperative mechanism with the more broadly expressed WNT3A.

What is the relationship between WNT8A expression and retinoic acid signaling?

The expression of WNT8A is significantly regulated by retinoic acid (RA) signaling, with research demonstrating that RA represses WNT8A expression in the developing embryo. Studies of RALDH2−/− embryos, which are deficient in RA synthesis and signaling, revealed strong upregulation and anterior expansion of caudal WNT8A expression . This observation was further confirmed in RDH10−/− embryos, which also exhibit RA signaling deficiency, where WNT8A expression was strongly upregulated at the 7-somite stage, with caudal and hindbrain expression domains merging into a single continuous domain .

The molecular mechanism underlying RA-mediated repression of WNT8A has been elucidated through genomic analysis and biochemical studies. A putative RA response element (RARE) of the DR2 class (direct repeat separated by 2 bp) was identified 4.9 kb upstream of the WNT8A transcription start site . Chromatin immunoprecipitation (ChIP) analysis using E8.5 mouse embryos demonstrated that all three RA receptors (RARα, RARβ, and RARγ) are recruited to this RARE in vivo .

This RA receptor-RARE interaction was further confirmed through electrophoretic mobility shift assays (EMSA) using nuclear protein extracts from E8.5 mouse embryos. The wild-type WNT8A RARE, but not a mutant version, was shifted by the nuclear extract, and super-shift assays using RAR-specific antibodies verified that the wild-type RARE binds all three RAR isoforms . These findings provide compelling evidence that RA repression of WNT8A is mediated directly through this RARE.

The functional significance of this RA-WNT8A regulatory relationship is highlighted by the phenotypic consequences of disrupted RA signaling. RALDH2−/− embryos display small somites and a shortened trunk, associated with loss of FGF8 repression and anterior shift in the caudal expression boundary of FGF8 . The upregulation of WNT8A in these embryos suggests that appropriate WNT8A expression boundaries, established through RA signaling, are critical for normal trunk development and somitogenesis.

What techniques are most effective for studying WNT8A protein-protein interactions?

Investigating WNT8A protein-protein interactions requires a multifaceted approach combining complementary techniques. Immunoprecipitation (IP) followed by mass spectrometry represents a powerful strategy for identifying novel WNT8A interacting partners. When performing IP experiments with WNT8A antibody, researchers should carefully optimize extraction conditions to preserve native protein conformations and interactions. Since WNT8A is a secreted signaling protein, analysis of both cellular lysates and conditioned media is advisable to capture the full spectrum of potential interactions.

For validation of specific interactions, co-immunoprecipitation (Co-IP) experiments can be conducted using WNT8A antibody for immunoprecipitation followed by Western blot detection of suspected interacting partners. Conversely, antibodies against suspected interacting proteins can be used for immunoprecipitation with subsequent WNT8A detection. Based on known WNT8A biology, members of the Frizzled receptor family represent primary interaction candidates, as WNT8A functions as a ligand for these seven transmembrane receptors .

Proximity ligation assay (PLA) offers a sensitive approach for visualizing protein-protein interactions in situ. This technique can be particularly valuable for detecting transient interactions within specific cellular compartments or tissues. When applying PLA to WNT8A studies, researchers should consider the secreted nature of WNT8A and optimize protocols to capture interactions both at the cell surface and potentially in extracellular matrices.

For investigating WNT8A-receptor interactions specifically, bioluminescence resonance energy transfer (BRET) or fluorescence resonance energy transfer (FRET) approaches can provide dynamic information about interaction kinetics in live cells. These techniques require generation of fusion constructs with appropriate energy donor and acceptor moieties, but offer unique insights into the temporal and spatial dynamics of WNT8A-receptor interactions.

Chromatin immunoprecipitation (ChIP) has been successfully applied to study interactions between RA receptors and the WNT8A regulatory region . This approach can be extended to investigate other transcription factors that may regulate WNT8A expression. The ChIP protocol described in the literature, utilizing antibodies against RARα, RARβ, and RARγ, provides a validated methodological framework that can be adapted for other potential transcriptional regulators .

How can researchers address common challenges in WNT8A antibody applications?

When working with WNT8A antibodies, researchers frequently encounter specific technical challenges that require systematic troubleshooting approaches. For Western blot applications, detection of multiple bands or unexpected molecular weights represents a common issue. While the calculated molecular weight of WNT8A is 39 kDa, the observed molecular weight typically ranges from 39-45 kDa . This variability may reflect post-translational modifications, alternative splicing, or proteolytic processing. To address this challenge, researchers should compare observed banding patterns with those reported in the literature and consider employing additional validation approaches such as siRNA knockdown or use of knockout controls.

Weak or absent signal in Western blot applications may result from insufficient protein loading, inadequate transfer efficiency, or suboptimal antibody dilution. Researchers should systematically optimize each parameter, beginning with loading increased protein amounts (up to 50-75 μg per lane) and validating with positive control samples from cell lines known to express WNT8A, such as Caco-2, HT-29, or SW480 cells .

For immunohistochemistry applications, high background staining presents a significant challenge. This issue may be addressed through extended blocking steps (1-2 hours at room temperature), inclusion of additional blocking agents such as normal serum matching the secondary antibody species, and careful optimization of primary and secondary antibody dilutions. The recommended dilution range of 1:50-1:500 for WNT8A antibody in IHC applications provides a starting point for systematic titration experiments.

Antigen retrieval optimization is particularly critical for successful WNT8A immunohistochemistry. While TE buffer at pH 9.0 is recommended, with citrate buffer at pH 6.0 as an alternative , researchers should compare multiple retrieval conditions in parallel to identify optimal protocols for their specific tissue samples and fixation conditions.

For immunofluorescence applications, autofluorescence can significantly confound WNT8A detection. Treatment with sodium borohydride or Sudan Black B prior to antibody incubation can effectively reduce autofluorescence in many tissue types. Additionally, selection of fluorophores with emission spectra distinct from the tissue's autofluorescence profile can enhance signal discrimination.

What are the recommended positive and negative controls for WNT8A antibody validation?

Rigorous validation of WNT8A antibodies requires thoughtfully selected positive and negative controls. For positive controls in Western blot applications, the literature identifies several cell lines with validated WNT8A expression, including Caco-2, HT-29, SW480 cells, and rat heart tissue . These systems provide reliable positive controls for initial antibody validation and ongoing experimental quality control.

For immunohistochemistry applications, human colon cancer tissue has been validated as a positive control for WNT8A detection . Researchers should maintain reference slides of this tissue type processed with standardized protocols to enable consistent comparison across experiments and antibody lots.

Negative controls for WNT8A antibody validation ideally include genetic knockout samples. The WNT8A knockout mouse line described in the literature carries a deletion encompassing all exons of WNT8A , providing an ideal negative control system. Tissues or cells derived from these knockout animals should exhibit complete absence of specific WNT8A signal across all application platforms.

When genetic knockout controls are unavailable, siRNA or shRNA knockdown systems offer alternative approaches for generating negative controls. Cells transfected with WNT8A-targeted siRNA/shRNA should exhibit significantly reduced signal compared to non-targeting control sequences, though residual signal may persist depending on knockdown efficiency and antibody specificity.

Technical negative controls should also be included in all experimental protocols. For immunohistochemistry and immunofluorescence applications, these include omission of primary antibody, substitution with non-specific IgG matching the host species and concentration of the primary antibody, and pre-adsorption controls where available. For Western blot, loading buffer-only lanes and irrelevant protein samples (from tissues known not to express WNT8A) serve as important technical controls.

Peptide competition assays provide an additional validation approach, where pre-incubation of the antibody with excess immunizing peptide should abolish specific signal. Information about the immunogen used for WNT8A antibody production (WNT8A fusion protein Ag29510) can guide design of such competition experiments.

How can researchers quantitatively analyze WNT8A expression across different experimental systems?

Quantitative analysis of WNT8A expression requires careful selection and optimization of analytical methodologies appropriate to the experimental question and biological system. For Western blot quantification, densitometric analysis represents a standard approach. Researchers should ensure linearity of signal detection by analyzing serial dilutions of positive control samples, establishing a standard curve that encompasses the expected range of experimental samples. Normalization to appropriate loading controls is essential, with selection of controls matched to the subcellular fraction being analyzed (cytosolic, membrane-associated, or secreted).

Quantitative PCR (qPCR) provides a complementary approach for measuring WNT8A expression at the transcript level. When designing qPCR experiments, researchers should select primers spanning exon-exon junctions to prevent amplification of genomic DNA and validate primer efficiency using standard curves. The GenBank accession number NM_001300938 for WNT8A provides reference sequence information for primer design.

For tissue-based expression analysis, quantitative immunohistochemistry offers valuable spatial information combined with expression level assessment. Digital image analysis using specialized software enables objective quantification of staining intensity and distribution. Standardization across experimental groups requires careful attention to consistent tissue processing, staining conditions, and image acquisition parameters.

ELISA assays represent another quantitative approach for WNT8A protein detection, particularly in biological fluids or cell culture supernatants. While commercial ELISA kits for WNT8A may be limited, researchers can develop sandwich ELISA systems using available antibodies, with the WNT8A antibody 30518-1-AP validated for ELISA applications .

For comparative analysis across experimental systems or conditions, researchers should consider establishing relative expression values rather than absolute quantification. This approach acknowledges the inherent variability in antibody affinity and detection sensitivity across different experimental platforms and biological contexts.

Statistical analysis of quantitative WNT8A expression data should employ appropriate tests based on data distribution and experimental design. For multiple group comparisons, analysis of variance (ANOVA) with suitable post-hoc tests is typically appropriate, while correlation analyses can illuminate relationships between WNT8A expression and other molecular or phenotypic parameters.

What are the emerging applications for WNT8A antibodies in cancer research?

WNT8A antibodies are increasingly employed in cancer research applications, particularly in studies investigating colorectal cancer biology. The validated detection of WNT8A in human colon cancer tissue and colorectal cancer cell lines including Caco-2, HT-29, SW480, and HCT 116 establishes a strong foundation for WNT8A investigation in this cancer type. Researchers are utilizing WNT8A antibodies to explore potential correlations between WNT8A expression levels and clinical parameters such as tumor stage, treatment response, and patient outcomes.

Immunohistochemical analysis of tumor tissue microarrays with WNT8A antibodies enables high-throughput assessment of expression patterns across large patient cohorts. This approach facilitates identification of potential associations between WNT8A expression and histopathological features, molecular subtypes, or clinical outcomes. The recommended dilution range of 1:50-1:500 for immunohistochemistry applications provides starting parameters for such studies.

Cancer stem cell research represents another emerging application area for WNT8A antibodies. Given the established role of WNT signaling in stem cell maintenance and the specific function of WNT8A in maintaining the axial stem cell niche in an undifferentiated state , researchers are investigating potential contributions of WNT8A to cancer stem cell phenotypes. Flow cytometry and immunofluorescence applications with WNT8A antibodies enable identification and characterization of potential WNT8A-expressing cancer stem cell populations.

Drug discovery programs targeting the WNT pathway are utilizing WNT8A antibodies to assess compound effects on WNT8A expression and downstream signaling. High-content screening platforms combining automated immunofluorescence with image analysis allow quantitative assessment of WNT8A expression changes in response to compound treatment. The validated immunofluorescence application of WNT8A antibody in HCT 116 cells provides a foundation for such screening approaches.

Mechanistic studies exploring the interaction between WNT8A signaling and other oncogenic pathways represent a particularly active research area. Co-immunoprecipitation experiments with WNT8A antibodies enable identification of novel protein-protein interactions that may contribute to cancer progression or treatment resistance. These studies have the potential to reveal new therapeutic targets or biomarkers for cancer diagnosis and monitoring.

How can WNT8A antibodies contribute to developmental biology research?

WNT8A antibodies provide valuable tools for investigating developmental processes, particularly in the context of body axis extension and patterning. The established role of WNT8A in cooperation with WNT3A to maintain FGF8 expression and prevent premature SOX2 upregulation in the axial stem cell niche highlights its significance in developmental biology research.

Immunohistochemical and immunofluorescence applications of WNT8A antibodies enable spatial and temporal mapping of protein expression throughout developmental processes. This approach complements in situ hybridization studies of WNT8A mRNA expression , providing integrated insight into transcriptional and post-transcriptional regulation of WNT8A during development.

Co-localization studies combining WNT8A antibody with antibodies against other developmental markers such as SOX2, FGF8, or lineage-specific transcription factors can reveal potential functional relationships between different signaling pathways. The validated immunofluorescence application of WNT8A antibody provides a foundation for such multi-parameter imaging studies.

The relationship between WNT8A expression and retinoic acid (RA) signaling represents a particularly rich area for developmental biology research. WNT8A antibodies can be employed to investigate protein-level consequences of RA signaling manipulation, complementing the established mRNA-level regulation through direct binding of RA receptors to the WNT8A regulatory region .

Transgenic animal models with reporter constructs driven by the WNT8A promoter enable in vivo monitoring of WNT8A expression dynamics. WNT8A antibodies provide complementary protein-level validation of reporter activity and enable more detailed investigation of specific cell populations or developmental stages of interest.

Emerging technologies such as single-cell proteomics and spatial transcriptomics offer new opportunities for investigating WNT8A function in development. WNT8A antibodies compatible with these platforms will enable integrated analysis of protein expression, localization, and co-expression patterns at unprecedented resolution, potentially revealing new insights into the cellular and molecular mechanisms of WNT8A function in development.

What are the future directions for WNT8A antibody development and applications?

Future developments in WNT8A antibody technology are likely to focus on enhanced specificity, versatility across applications, and compatibility with emerging research platforms. The development of monoclonal antibodies with epitope specifications targeting different domains of the WNT8A protein would provide researchers with tools for more precise functional studies, potentially distinguishing between different post-translational modifications or protein conformations.

Antibodies specifically recognizing the active, signaling-competent form of WNT8A would be particularly valuable for functional studies. Such conformation-specific antibodies could enable direct assessment of WNT8A signaling activity, rather than merely protein presence, providing deeper insight into pathway regulation and function.

Enhanced compatibility with multiplexed imaging platforms represents another important direction for WNT8A antibody development. Antibodies compatible with techniques such as multiplex immunohistochemistry, imaging mass cytometry, or CODEX would enable simultaneous visualization of WNT8A alongside numerous other markers, facilitating comprehensive analysis of signaling network interactions in complex tissues.

The development of WNT8A antibodies specifically validated for challenging applications such as chromatin immunoprecipitation sequencing (ChIP-seq) or proximity labeling approaches would expand the toolbox for investigating WNT8A regulatory networks and protein interactions. While ChIP has been successfully applied to study the WNT8A regulatory region , application of ChIP-seq with transcription factor antibodies to this locus would provide genome-wide insights into WNT8A regulatory networks.

Species cross-reactivity represents another important consideration for future antibody development. The current WNT8A antibody 30518-1-AP shows reactivity with human and rat samples , but expanded validation across additional species would enhance its utility for comparative developmental and evolutionary studies.

Integration of WNT8A antibodies with emerging single-cell analysis platforms would enable unprecedented resolution in studying WNT8A expression heterogeneity within tissues. Antibodies compatible with single-cell Western blot, single-cell proteomics, or in situ protein sequencing technologies would facilitate characterization of WNT8A expression at the individual cell level, potentially revealing new insights into cellular heterogeneity and microenvironmental influences on WNT8A expression and function.